Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,100 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SOC (standard of care) Clear all
Recruiting No phase listed Observational

BIO-FUNCTION for Prediction Non Relapse Mortality in Transplant and Cell Therapy

NCT07769151
View directory record Official record
Conditions
Mortality Prediction
Interventions
blood sample to check CXCL9 pre stem cell transplant and cell therapy
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 28, 2026, 11:59 AM EDT
Completed Not applicable Interventional Results available

Tough Talks: A Disclosure Intervention for HIV+ Young Men Who Have Sex With Men (YMSM)

NCT03414372
View directory record Official record
Conditions
Hiv, HIV/AIDS, Disclosure
Interventions
Tough Talks Online, Tough Talks Clinic, Standard of Care
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 29 Years · Male only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 28, 2026, 11:59 AM EDT
Not listed Not applicable Interventional

Assessment of the Effects on the Skin Microbiome of Amending an Over-the-counter Eczema Product With Activated Oil (AO)

NCT05413395
View directory record Official record
Conditions
Eczema
Interventions
topical colloidal oatmeal formulation with a modified plant oil, topical colloidal oatmeal formulation
Other
Lead sponsor
GlycosBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Sep 28, 2026, 11:59 AM EDT
Active, not recruiting Not applicable Interventional

A Behavioral mHealth Intervention for People With HIV With Anxiety and Depression

NCT07112001
View directory record Official record
Conditions
HIV, Depression, Anxiety
Interventions
PositiveLinks with Counseling, Standard of Care (SOC)
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 28, 2026, 11:59 AM EDT
Not listed Phase 2 Interventional

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

NCT02446093
View directory record Official record
Conditions
Borderline Resectable Pancreatic Adenocarcinoma
Interventions
Aglatimagene besadenovec, Chemoradiation, Stereotactic body radiation therapy, Surgery
Biological · Radiation · Procedure
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Fort Myers, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2024 · Synced Sep 28, 2026, 11:59 AM EDT
Completed Not applicable Interventional

Nativis Voyager for Newly Diagnosed GBM

NCT03276286
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Nativis Voyager
Device
Lead sponsor
Nativis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Tucson, Arizona • Encinitas, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 28, 2026, 11:59 AM EDT
Recruiting Phase 1 Interventional

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT06441331
View directory record Official record
Conditions
Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor, GIST
Interventions
Lutetium Lu 177-Edotreotide, Amino Acid Solution
Drug · Other
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
24 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
4
States / cities
San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 28, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

NCT04663737
View directory record Official record
Conditions
Covid19
Interventions
Silmitasertib, SOC
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 28, 2026, 11:59 AM EDT
Completed Not applicable Interventional Results available

Retrospective Independent Safety Review of Closed Irrisept Study

NCT05359666
View directory record Official record
Conditions
Adverse Events
Interventions
Irrisept, Standard of Care
Device
Lead sponsor
Irrimax Corporation
Industry
Eligibility
Not listed
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 28, 2026, 11:59 AM EDT
Recruiting Not applicable Interventional

Impact of a Multiplex Respiratory PCR Test on Outcomes for Patients Presenting With Respiratory Illness in the Urgent Care Setting: A Hybrid-Effectiveness Quasi-Experimental Trial

NCT07513519
View directory record Official record
Conditions
Acute Respiratory Infections (ARIs)
Interventions
SPOTFIRE R/ST Diagnostic Test
Device
Lead sponsor
BioMérieux
Industry
Eligibility
1 Year and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Gardendale, Alabama • Hoover, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 28, 2026, 11:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated

NCT05045183
View directory record Official record
Conditions
Wound Healing
Interventions
SoC Adhesive Bandage, Antibiotic Ointment, Antiseptic Wash, Hydrocolloid Pad
Device · Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Sep 28, 2026, 11:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment

NCT01506141
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Idursulfase-IT, Elaprase
Drug
Lead sponsor
Takeda
Industry
Eligibility
3 Years to 18 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
7
States / cities
Chicago, Illinois • Chapel Hill, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 28, 2026, 11:59 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis

NCT03148756
View directory record Official record
Conditions
Endocarditis, Bacteremia
Interventions
Dalbavancin, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Ft. Pierce, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 28, 2026, 11:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

NCT05405595
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumors
Interventions
ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab), Standard of care (Fruquintinib)
Drug
Lead sponsor
Adagene Inc
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Duarte, California • Irvine, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 28, 2026, 11:59 AM EDT
Terminated Phase 2 Interventional Results available

A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients

NCT03780543
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 71 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Beverly Hills, California • Coronado, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Sep 28, 2026, 11:59 AM EDT
Terminated No phase listed Observational

Localized Alveolar Ridge Augmentation With Space Maintenance Devices

NCT00991432
View directory record Official record
Conditions
Alveolar Bone Loss
Interventions
INFUSE® Bone Graft
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Greenwood Village, Colorado • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Sep 28, 2026, 11:59 AM EDT
Terminated No phase listed Observational

Sinus Augmentation With Dental Implant

NCT00991393
View directory record Official record
Conditions
Maxillary Sinus Bone Loss
Interventions
INFUSE® Bone Graft
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Fullerton, California • Denver, North Carolina • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Sep 28, 2026, 11:59 AM EDT
Completed No phase listed Observational

Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel

NCT05541328
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tisagenlecleucel
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Sep 28, 2026, 11:59 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study

NCT03726307
View directory record Official record
Conditions
Kidney Transplant, Renal Transplant Recipients
Interventions
DCreg: 0.5 million cells/kg+SOC, DCreg: 1.2 million cells/kg+SOC, DCreg:2.5 to 5.0 million cells/kg+SOC
Biological
Lead sponsor
Angus W. Thomson PhD DSc
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 28, 2026, 11:59 AM EDT
Not listed No phase listed Observational

Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort

NCT05295277
View directory record Official record
Conditions
Developmental Disability, Intellectual Disability, Autism Spectrum Disorder, Congenital Anomaly, Fragile X Syndrome, Facioscapulohumeral Muscular Dystrophy 1
Interventions
Standard of care genetic testing group
Other
Lead sponsor
Bionano Genomics
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Atlanta, Georgia • Augusta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 28, 2026, 11:59 AM EDT
Completed Phase 2 Interventional

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

NCT05593328
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Colorectal Cancer
Interventions
Onvansertib, FOLFIRI, Bevacizumab
Drug
Lead sponsor
Cardiff Oncology
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
27
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Sep 28, 2026, 11:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

NCT04421378
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine
Drug · Radiation · Device
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 28, 2026, 11:59 AM EDT
Active, not recruiting Phase 3 Interventional

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

NCT04994717
View directory record Official record
Conditions
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Interventions
Blinatumomab, Low-intensity chemotherapy regimen, SOC chemotherapy regimen
Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years to 100 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
7
States / cities
Duarte, California • Orange, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 28, 2026, 11:59 AM EDT
Recruiting No phase listed Observational

Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring

NCT06668935
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists
Device
Lead sponsor
Abbott Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 28, 2026, 11:59 AM EDT